DE69432031D1 - Huntingtin-DNA, Protein und Verwendung - Google Patents

Huntingtin-DNA, Protein und Verwendung

Info

Publication number
DE69432031D1
DE69432031D1 DE69432031T DE69432031T DE69432031D1 DE 69432031 D1 DE69432031 D1 DE 69432031D1 DE 69432031 T DE69432031 T DE 69432031T DE 69432031 T DE69432031 T DE 69432031T DE 69432031 D1 DE69432031 D1 DE 69432031D1
Authority
DE
Germany
Prior art keywords
huntingtin
protein
dna
huntingtin dna
huntington
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69432031T
Other languages
English (en)
Inventor
Marcy E Macdonald
Christine M Ambrose
Mabel P Duyao
James F Gusella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of DE69432031D1 publication Critical patent/DE69432031D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69432031T 1993-03-05 1994-03-07 Huntingtin-DNA, Protein und Verwendung Expired - Lifetime DE69432031D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2749893A 1993-03-05 1993-03-05
US8500093A 1993-07-01 1993-07-01

Publications (1)

Publication Number Publication Date
DE69432031D1 true DE69432031D1 (de) 2003-02-27

Family

ID=26702551

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432031T Expired - Lifetime DE69432031D1 (de) 1993-03-05 1994-03-07 Huntingtin-DNA, Protein und Verwendung

Country Status (7)

Country Link
US (2) US5686288A (de)
EP (1) EP0614977B1 (de)
JP (1) JPH0767661A (de)
AT (1) ATE231551T1 (de)
AU (1) AU676001B2 (de)
CA (1) CA2116280A1 (de)
DE (1) DE69432031D1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955265A (en) * 1992-02-06 1999-09-21 Massachusetts Institute Of Technology DNA sequence encoding the myotonic dystrophy gene and uses thereof
US5977333A (en) * 1992-02-06 1999-11-02 Massachusetts Institute Of Technology DNA sequence encoding the myotonic dystrophy gene and uses thereof
US5635351A (en) * 1995-03-14 1997-06-03 The Regents Of The University Of California Genetic gain and loss in gliomas
US6093549A (en) * 1995-11-09 2000-07-25 The Johns Hopkins University Huntingtin-associated protein-related assays
WO1997018825A1 (en) * 1995-11-17 1997-05-29 The University Of British Columbia PROTEIN WHICH INTERACTS WITH THE HUNTINGTON'S DISEASE GENE PRODUCT, cDNA CODING THEREFOR, AND ANTIBODIES THERETO
DE69739956D1 (de) 1996-09-11 2010-09-16 Univ Oregon Health Sciences Calciumaktivierter Kaliumkanal mit zwischenzeitlicher Konduktanz und Verwendungen davon
AU7180498A (en) 1996-11-15 1998-06-03 University Of Massachusetts Huntingtin-related therapeutics and bioassay
US7799535B1 (en) 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
US6355481B1 (en) 1999-06-18 2002-03-12 Emory University Hybridoma cell line and monoclonal antibody for huntingtin protein
JP2003531570A (ja) * 1999-07-27 2003-10-28 アブジェニックス インク． 神経障害に関連したポリペプチド蓄積を阻害する方法および組成物
FR2797055B1 (fr) * 1999-07-29 2003-10-03 Fond Jean Dausset Ceph Procede de criblage de molecules destinees au traitement de la maladie de huntington
WO2001079283A1 (en) * 2000-04-13 2001-10-25 University Of British Columbia Modulating cell survival by modulating huntingtin function
ATE532874T1 (de) * 2001-02-15 2011-11-15 Univ Chicago Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen
US7375194B2 (en) * 2002-01-28 2008-05-20 California Institute Of Technology Antibodies that bind to an epitope on the Huntington's disease protein
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20050106731A1 (en) * 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
US20050042646A1 (en) * 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20080176812A1 (en) * 2002-08-05 2008-07-24 Davidson Beverly L Allele-specific silencing of disease genes
US20040023390A1 (en) * 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
US20050255086A1 (en) * 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US7605249B2 (en) * 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
GB0228079D0 (en) * 2002-12-02 2003-01-08 Laxdale Ltd Huntington's Disease
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
EP1617829A4 (de) * 2003-04-16 2009-11-11 Whitehead Biomedical Inst Hefe mit ektopischer expression von abnormal verarbeiteten proteinen und anwendungen dafür
US7589189B2 (en) 2003-05-14 2009-09-15 Japan Science And Technology Agency Inhibition of the expression of huntingtin gene
US8680063B2 (en) * 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
US20070105803A1 (en) * 2005-08-18 2007-05-10 Muthiah Manoharan Methods and compositions for treating neurological disease
US7320965B2 (en) * 2005-10-28 2008-01-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Huntingtin gene
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (de) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Mittel und Verfahren zur Induktion von Exon-skipping
US9273356B2 (en) * 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
PT2049664E (pt) 2006-08-11 2012-01-03 Prosensa Technologies Bv Oligonucleotídeos de cadeia simples complementares dos elementos repetitivos para tratar perturbações genéticas associadas à instabilidade das repetições do adn
WO2009008725A2 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
CA2693048C (en) 2007-07-12 2016-10-18 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs or tissues
CA2704049A1 (en) 2007-10-26 2009-04-30 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
NZ587178A (en) 2008-02-08 2011-11-25 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2119783A1 (de) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
AU2010239779A1 (en) 2009-04-24 2011-11-17 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating DMD
WO2011023827A1 (en) * 2009-08-31 2011-03-03 Centre National De La Recherche Scientifique Purification process of nascent dna
US10131913B2 (en) 2009-08-31 2018-11-20 Centre National De La Recherche Scientifique Purification process of nascent DNA
KR101774526B1 (ko) * 2009-09-11 2017-09-04 아이오니스 파마수티컬즈, 인코포레이티드 헌팅틴 발현의 조절
JP6141018B2 (ja) 2009-12-24 2017-06-07 バイオマリン テクノロジーズ ベー．フェー． 炎症性障害を治療するための分子
CA2862628C (en) 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
EP3174898A2 (de) 2014-07-29 2017-06-07 Neurimmune Holding AG Vom menschen abgeleitete anti-huntingtin-(htt)-antikörper und verwendungen davon
JP2020537514A (ja) * 2017-10-02 2020-12-24 オックスフォード バイオダイナミックス リミテッド バイオマーカー

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) * 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
CA2092455A1 (en) * 1993-03-25 1994-09-26 Johanna M. Rommens Process for isolating genes and the gene causative of huntington disease

Also Published As

Publication number Publication date
US5686288A (en) 1997-11-11
AU5642994A (en) 1994-09-08
EP0614977A3 (en) 1996-02-28
AU676001B2 (en) 1997-02-27
ATE231551T1 (de) 2003-02-15
EP0614977B1 (de) 2003-01-22
EP0614977A2 (de) 1994-09-14
CA2116280A1 (en) 1994-09-06
US5693757A (en) 1997-12-02
JPH0767661A (ja) 1995-03-14

Similar Documents

Publication Publication Date Title
DE69432031D1 (de) Huntingtin-DNA, Protein und Verwendung
CY1111950T1 (el) 32 ανθρωπινες εκκρινομενες πρωτεϊνες
DE3886060D1 (de) Vorläuferprotein des APC-Polypeptids, dafür codierende DNA und diagnostische Verwendung der DNA und des Proteins.
GR3030811T3 (en) Proteins produced by human lymphocytes, dna sequence coding these proteins, and pharmaceutical and biological uses thereof
NL300273I1 (nl) DNA dat humaan papillomavirus type 18 codeert.
WO1998039446A3 (en) 70 human secreted proteins
WO1998039448A3 (en) 186 human secreted proteins
WO1998040483A3 (en) 28 human secreted proteins
ATE241014T2 (de) Hiv-2 varianten
DE69424209D1 (de) Tumorsuppressor-Gen Merlin und dessen Verwendungen
EP1042342A4 (de) 53 proteine menschlichen ursprungs
PT816504E (pt) Acetil-hidrolase para o factor activador das plaquetas, e seu gene
DE69728897D1 (de) Saeugetierchemokine
SE9002212D0 (sv) Igg binding protein
EP1538161A3 (de) 32 humane sekretierte Proteine
EP1557425A9 (de) Humanes sekeretiertes Protein
EP1394252A3 (de) 70 Humane sekretierte Proteine
EP1333092A3 (de) 28 menschlich sekretierte Proteine
EP1428833A3 (de) 207 menschliche sekretierte Proteine
EP1439224A3 (de) 67 humane sekretierte Proteine

Legal Events

Date Code Title Description
8332 No legal effect for de